BioSpace News Archive

Taysha Gene Therapies today announced that it has been granted orphan drug designation from the European Commission for TSHA-102, an AAV9-based gene replacement therapy in development for Rett syndrome.

Vivos Therapeutics, Inc. today announced that Vivos’ Chairman and Chief Executive Officer, Kirk Huntsman, and Vivos’ Chief Financial Officer, Brad Amman, will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 pm EST on Wednesday, September 29, 2021.

Statera Biopharma, Inc. will participate in the Benzinga Virtual Healthcare Small Cap Conference taking place September 29-30, 2001

BetterLife Pharma Inc. announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc., and Pontificia Universidad Católica de Chile have enrolled the first patient in the Phase 1 portion of the Phase 1-2 randomized placebo controlled in COVID-19 patients.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Virtual Global Healthcare Conference being hosted by the Cantor Fitzgerald Healthcare team September 27 – 30, 2021.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preliminary safety and efficacy data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC).

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), today announced topline data results from the newly-diagnosed adjuvant arm of its open-label, Phase 2 clinical study being conducted at the MD Anderson Cancer Center (MD Anderson) in Houston, Texas.

Spectrum Pharmaceuticals today announced that management will participate in the 2021 Cantor Virtual Global Healthcare Conference. A fireside chat is scheduled for Wednesday, September 29, 2021, at 1:20 p.m. ET.

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M.D., as Chief Medical Officer. Dr. Denis brings more than 25 years of clinical development and oncology expertise to Verastem.

Dynavax Technologies Corporation today announced that Clover Biopharmaceuticals (Clover) reported positive data for their protein-based COVID-19 vaccine candidate, SCB-2019